21:57 , Sep 21, 2018 |  BC Extra  |  Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...
16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial showing that anti-PD-1 antibody sintilimab (IBI308) plus Alimta...
00:17 , Sep 15, 2018 |  BioCentury  |  Finance

Hua’s institutional advantage

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical candidates...
19:02 , Aug 30, 2018 |  BioCentury  |  Finance

Building a deeper Harbour

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals. Singapore sovereign wealth fund GIC led the...
19:47 , Aug 20, 2018 |  BC Extra  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Monday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical candidates in...
03:06 , Aug 8, 2018 |  BC Extra  |  Financial News

BeiGene dips slightly in Hong Kong debut

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) slipped HK$1 to HK$107 in its first day of trading on the Hong Kong exchange Wednesday. Last week, the company raised HK$7.1 billion ($902.7 million) by pricing its Hong Kong listing...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
17:36 , Aug 3, 2018 |  BC Extra  |  Financial News

Ascletis ends first trading week on downturn

Ascletis Pharma Inc. (HKSE:1672) sank HK$1.84 (16%) to HK$10.02 on Friday, ending its first week of trading down 28% from its IPO price of HK$14. This week, Ascletis became the first biotech to go public on...
16:40 , Aug 3, 2018 |  BC Week In Review  |  Financial News

BeiGene prices Hong Kong listing

BeiGene Ltd. (NASDAQ:BGNE) raised on Aug. 2 HK$7.1 billion (US$902.7 million) through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. BeiGene, which priced the offering toward...